Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world immune crossover or rechallenge in recurrent/metastatic esophageal cancer
ChiCTR2500110645Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (4 cohorts), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500110645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110645.